OTCMKTS:ONCS
Delisted
OncoSec Medical Incorporated Stock News
$0.277
+0 (+0%)
At Close: Sep 22, 2023
OncoSec to Present at Virtual Summer Investor Summit
01:00pm, Thursday, 04'th Jun 2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chi
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
01:00pm, Wednesday, 03'rd Jun 2020
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from aroun
The
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System
01:00pm, Wednesday, 27'th May 2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance for three new patent
OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical dat
Normal People: Marianne’s Italian villa is now available to rent on Airbnb
11:00am, Thursday, 21'st May 2020
Could it be a perfect spot for your own lingering glances or unspeakably tense dinner party?
OncoSec Partners with the Melanoma Research Foundation to Host Live Panel Discussion during Melanoma Awareness Month
01:00pm, Thursday, 14'th May 2020
OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its partnering with the Melanoma Research Foundation (MRF) to rai
OncoSec Medical Incorporated (Nasdaq:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the European Medicines Agency (EMA) issued
Oncosec Medical Incorporated (the "Company" or "Oncosec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced published data in Clinical Cancer Researc
OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced pre-clinical data from a feasibility study of its visceral
OncoSec Appoints Renowned Oncologist and Immunologist, Herbert Kim Lyerly, M.D., Duke University, to its Board of Directors
01:00pm, Monday, 20'th Apr 2020
OncoSec Medical Incorporated (Nasdaq:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the appointment of Herbert Kim Lyerly, M.D
Healthcare firms pile on initiatives as COVID-19 pandemic advances
02:38pm, Monday, 06'th Apr 2020
Pfizer (PFE +1.9%) and The Pfizer Foundation commit to donate $40M in medical and charitable grants to help fight the pandemic in the U.S. and around the world.CVS Health (CVS +1.7%) has opened drive-
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral DNA‑based cancer immunotherapies, today announced that Providence Cancer Institu
OncoSec Medical Incorporated to Present at the New York City based Investor Summit on March 25th-26th
01:00pm, Friday, 20'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 20, 2020 / OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O
OncoSec Announces Publication of Positive TAVO™ Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncology
12:30pm, Tuesday, 17'th Mar 2020
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of positive TAVO™ monoth
